News headlines about CONMED (NASDAQ:CNMD) have trended somewhat positive on Friday, Accern reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. CONMED earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned media headlines about the medical technology company an impact score of 47.286262925507 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Shares of CONMED (NASDAQ:CNMD) opened at $52.03 on Friday. CONMED has a twelve month low of $39.74 and a twelve month high of $54.77. The firm has a market capitalization of $1,428.54, a price-to-earnings ratio of 92.91, a P/E/G ratio of 2.93 and a beta of 0.66. The company has a current ratio of 2.56, a quick ratio of 1.49 and a debt-to-equity ratio of 0.84.
CONMED (NASDAQ:CNMD) last released its quarterly earnings results on Thursday, November 2nd. The medical technology company reported $0.42 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.41 by $0.01. CONMED had a return on equity of 8.40% and a net margin of 1.99%. The firm had revenue of $190.10 million during the quarter, compared to analysts’ expectations of $187.13 million. During the same period last year, the firm posted $0.41 EPS. The business’s revenue was up 2.9% on a year-over-year basis. equities analysts anticipate that CONMED will post 1.86 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, January 5th. Investors of record on Friday, December 15th will be issued a dividend of $0.20 per share. The ex-dividend date is Thursday, December 14th. This represents a $0.80 dividend on an annualized basis and a yield of 1.54%. CONMED’s dividend payout ratio is 142.86%.
A number of equities analysts have recently issued reports on CNMD shares. Zacks Investment Research cut CONMED from a “hold” rating to a “sell” rating in a report on Monday, November 6th. Needham & Company LLC reissued a “buy” rating and issued a $58.00 target price on shares of CONMED in a report on Friday, November 17th. KeyCorp reissued a “hold” rating on shares of CONMED in a report on Friday, November 3rd. Piper Jaffray Companies reissued a “hold” rating and issued a $46.00 target price on shares of CONMED in a report on Friday, November 3rd. Finally, BidaskClub cut CONMED from a “hold” rating to a “sell” rating in a report on Tuesday, December 12th. One analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $52.25.
In other news, EVP Luke A. Pomilio sold 10,020 shares of CONMED stock in a transaction on Friday, November 3rd. The stock was sold at an average price of $53.57, for a total value of $536,771.40. Following the completion of the sale, the executive vice president now directly owns 44,472 shares of the company’s stock, valued at approximately $2,382,365.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Luke A. Pomilio sold 29,363 shares of CONMED stock in a transaction on Thursday, November 9th. The shares were sold at an average price of $50.70, for a total value of $1,488,704.10. Following the completion of the sale, the executive vice president now directly owns 45,486 shares of the company’s stock, valued at $2,306,140.20. The disclosure for this sale can be found here. Insiders have sold a total of 51,812 shares of company stock valued at $2,654,756 over the last ninety days. Insiders own 2.62% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “CONMED (CNMD) Getting Somewhat Favorable Press Coverage, Analysis Shows” was originally posted by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://transcriptdaily.com/2018/01/05/conmed-cnmd-getting-somewhat-favorable-press-coverage-analysis-shows.html.
CONMED Company Profile
CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology.
Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.